A Phase I Study of YY-20394 in Patients With B Cell Hematologic Malignancies

Clinical trial NCT03757000 · UNKNOWN

Trial details

NCT number: NCT03757000
Sponsor: Shanghai YingLi Pharmaceutical Co. Ltd.
Status: UNKNOWN
Phase: Phase 1
Study type: INTERVENTIONAL

B-cell Lymphoma Recurrent B-cell Chronic Lymphocytic Leukemia

Start date: 2017-12-25
Primary completion: 2019-03-30
Enrollment: 42

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.